studies are often heterogeneous. One way that this can be overcome in CAM research is by collaborating using a prospective MA (PMA) design. In a PMA, trials are identified, evaluated, and determined prior to publication to establish eligibility for a post-trial MA, therefore, allowing prestandardization of information required for the post-hoc MA. The PMA is a way of building the CAM evidence base in the absence of being able to conduct large, full-scale trials.
Arguably, this approach takes more organizing and collaboration at a very early stage in research. This may take the form of liaising with other researchers within a discipline, nationally and internationally, to write the protocol initially, and having maintenance meetings to ensure a continuum of a study protocol. Any divergence from protocol for any reason would be discussed with the PMA group. However, in the absence of funders giving large grants to run fully powered RCTs to explore the efficacy of complementary therapies, I believe that this is the only way forward in forming an evidence base. A good resource for researchers who are interested in this methodology can be found here:
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